PPMS and SPMS: Epidemiology and Market Forecasts to 2030 by Pharmascroll
"PPMS and SPMS: Epidemiology and Market Forecasts to 2030" reports cover in depth disease insights, epidemiology overview and markets and drug forecasts country wise till 2030.
Hyderabad, India, April 25, 2018 --(PR.com)-- Multiple Sclerosis is an autoimmune disorder that happens in the Central nervous system of the body. Multiple Sclerosis involves the brain, optic nerves and the spinal cord and leads to the destruction of the insulation layer, Myelin, which covers the nerve fibers in the CNS.
SPMS: Epidemiology and Market Forecasts to 2030
SPMS is characterized by a continuous increase in disability and worsening of symptoms with or without the period of relapses and remissions. As per the latest report by Pharmascroll, SPMS- A Detailed Overview, nearly 50% of RRMS patients progress to SPMS in a 10 year time period. In SPMS, the patients might not have relapses at all but the symptoms may not completely go off (plateau) in the remission period.
The report delivers an in-depth understanding of the disease, historical & forecasted epidemiology of Secondary Progressive MS in the US, EU5, and Japan and the historical & forecasted market size of SPMS drug wise in $ sales and patient numbers at global level and in the US, EU5 (Germany, France, Italy, Spain, UK), Australia and Canada till 2030.
Drugs covered:
Laquinimod
Lemtrada
Masitinib
Ocrelizumab
Tysabri
Siponimod
Zinbryta
Mitoxantrone
SPMS Epidemiology:
As per the report, SPMS is prevalent in around 30% of the MS patients and around 50% of RRMS patients move on to progress to the SPMS stage in a span of around 10 years and around 85% of the patients progress to SPMS stage in the span of 15-20 years. The report provides the overview of SPMS diagnosed prevalent and treated patients in the US, EU5 and Japan markets year wise starting from 2015 till 2024.
Market Forecast in $ Sales and Patient numbers:
The report forecasts that the SPMS market is projected to reach over $3 Bn by 2022 primarily due to the uptake of key molecules including Siponimod and Ocrevus in SPMS.The report provides sales and patient numbers forecast for the overall SPMS market and drug wise forecasts from 2015 till 2030 at Global level and in the US, EU5, Australia and Canada markets.
The report can be checked at https://pharmascroll.com/product/spms-detailed-overview/
PPMS: Epidemiology and Market Forecasts to 2030
Primary progressive multiple sclerosis is primarily characterized by progression of disease activity and the disability amongst the patients. As per the latest report by Pharmascroll, PPMS- A Detailed Overview, nearly 10-15% of the multiple sclerosis patients are Primary Progressive MS patients. The Primary Progressive MS patients might have an active or non-active progression of disease.
This report delivers an in-depth understanding of the disease, historical & forecasted epidemiology of Primary Progressive MS in the US, EU5, and Japan and the historical & forecasted market size of PPMS drug wise in $ sales and patient numbers at global level and in the US, EU5 (Germany, France, Italy, Spain, UK), Australia and Canada till 2030.
Drugs covered:
Laquinimod
Ocrelizumab
Masitinib
Lemtrada
Qizenday
Ibudilast
Idebenone
PPMS Epidemiology:
As per the report, nearly 10-15% of the Multiple Sclerosis patients are PPMS patients and in the US, around 12-13% of the MS patients are PPMS patients. The report provides the overview of PPMS diagnosed prevalent and treated patients in the US, EU5 and Japan market year wise starting from 2015 till 2024.
Market Forecast in $ Sales and Patient numbers:
The report forecasts that the PPMS market is projected to reach over $2 Bn by 2024 primarily due to the launch and uptake of key molecules including Ocrevus in PPMS. The report provides sales and patient numbers forecast for the overall PPMS market and drug wise forecasts from 2015 till 2030 at Global level and in the US, EU5, Australia and Canada markets.
The report can be checked at https://pharmascroll.com/product/ppms-detailed-overview/
Why Purchase the Reports:
· Robust Market and Drug forecast available at country level
· Forecast in terms of both $ sales and Patient Numbers
· Current and Forecasted Drug treated and Diagnosed Prevalent Patient pool
· Detailed Drug Attribute analysis on multiple Clinical Parameters
· Multiple Countries coverage
· Current Marketed and Pipeline Drugs coverage
· Detailed Disease Insights coverage
To purchase the reports at a special bundle pack price offer, the interested buyers can write back to the company at enquiry@pharmascroll.com
About Pharmascroll:
Pharmascroll is a diligent business consulting and market research firm focused solely towards pharmaceutical markets. The company consults and researches in majorly chronic disease indications prevalent across the globe. The research conducted by Pharmascroll analysts is targeted to provide analytical and logical answers to the key business questions of the pharmaceutical and medical insights teams and to make better informed business decisions with the detailed relevant information available.
SPMS: Epidemiology and Market Forecasts to 2030
SPMS is characterized by a continuous increase in disability and worsening of symptoms with or without the period of relapses and remissions. As per the latest report by Pharmascroll, SPMS- A Detailed Overview, nearly 50% of RRMS patients progress to SPMS in a 10 year time period. In SPMS, the patients might not have relapses at all but the symptoms may not completely go off (plateau) in the remission period.
The report delivers an in-depth understanding of the disease, historical & forecasted epidemiology of Secondary Progressive MS in the US, EU5, and Japan and the historical & forecasted market size of SPMS drug wise in $ sales and patient numbers at global level and in the US, EU5 (Germany, France, Italy, Spain, UK), Australia and Canada till 2030.
Drugs covered:
Laquinimod
Lemtrada
Masitinib
Ocrelizumab
Tysabri
Siponimod
Zinbryta
Mitoxantrone
SPMS Epidemiology:
As per the report, SPMS is prevalent in around 30% of the MS patients and around 50% of RRMS patients move on to progress to the SPMS stage in a span of around 10 years and around 85% of the patients progress to SPMS stage in the span of 15-20 years. The report provides the overview of SPMS diagnosed prevalent and treated patients in the US, EU5 and Japan markets year wise starting from 2015 till 2024.
Market Forecast in $ Sales and Patient numbers:
The report forecasts that the SPMS market is projected to reach over $3 Bn by 2022 primarily due to the uptake of key molecules including Siponimod and Ocrevus in SPMS.The report provides sales and patient numbers forecast for the overall SPMS market and drug wise forecasts from 2015 till 2030 at Global level and in the US, EU5, Australia and Canada markets.
The report can be checked at https://pharmascroll.com/product/spms-detailed-overview/
PPMS: Epidemiology and Market Forecasts to 2030
Primary progressive multiple sclerosis is primarily characterized by progression of disease activity and the disability amongst the patients. As per the latest report by Pharmascroll, PPMS- A Detailed Overview, nearly 10-15% of the multiple sclerosis patients are Primary Progressive MS patients. The Primary Progressive MS patients might have an active or non-active progression of disease.
This report delivers an in-depth understanding of the disease, historical & forecasted epidemiology of Primary Progressive MS in the US, EU5, and Japan and the historical & forecasted market size of PPMS drug wise in $ sales and patient numbers at global level and in the US, EU5 (Germany, France, Italy, Spain, UK), Australia and Canada till 2030.
Drugs covered:
Laquinimod
Ocrelizumab
Masitinib
Lemtrada
Qizenday
Ibudilast
Idebenone
PPMS Epidemiology:
As per the report, nearly 10-15% of the Multiple Sclerosis patients are PPMS patients and in the US, around 12-13% of the MS patients are PPMS patients. The report provides the overview of PPMS diagnosed prevalent and treated patients in the US, EU5 and Japan market year wise starting from 2015 till 2024.
Market Forecast in $ Sales and Patient numbers:
The report forecasts that the PPMS market is projected to reach over $2 Bn by 2024 primarily due to the launch and uptake of key molecules including Ocrevus in PPMS. The report provides sales and patient numbers forecast for the overall PPMS market and drug wise forecasts from 2015 till 2030 at Global level and in the US, EU5, Australia and Canada markets.
The report can be checked at https://pharmascroll.com/product/ppms-detailed-overview/
Why Purchase the Reports:
· Robust Market and Drug forecast available at country level
· Forecast in terms of both $ sales and Patient Numbers
· Current and Forecasted Drug treated and Diagnosed Prevalent Patient pool
· Detailed Drug Attribute analysis on multiple Clinical Parameters
· Multiple Countries coverage
· Current Marketed and Pipeline Drugs coverage
· Detailed Disease Insights coverage
To purchase the reports at a special bundle pack price offer, the interested buyers can write back to the company at enquiry@pharmascroll.com
About Pharmascroll:
Pharmascroll is a diligent business consulting and market research firm focused solely towards pharmaceutical markets. The company consults and researches in majorly chronic disease indications prevalent across the globe. The research conducted by Pharmascroll analysts is targeted to provide analytical and logical answers to the key business questions of the pharmaceutical and medical insights teams and to make better informed business decisions with the detailed relevant information available.
Contact
Pharmascroll Research and Consulting Private Limited
Bhawna Gupta
+919776868067
www.pharmascroll.com
Bhawna Gupta
+919776868067
www.pharmascroll.com
Contact
Categories